Drug profile · INN
letrozole
ARX-LETROZOLE
letrozole (ARX-LETROZOLE) is a cytochrome p450 19a1 inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Drug details — letrozole
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 47
- Data quality
- 0.89
Quick answer
letrozole (ARX-LETROZOLE) is a cytochrome p450 19a1 inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cytochrome P450 19A1 inhibitor
Primary target: Aromatase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is letrozole?
letrozole (ARX-LETROZOLE) is a cytochrome p450 19a1 inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for letrozole?
ARX-LETROZOLE is a marketed brand name for letrozole. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of letrozole?
letrozole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.